42 unknown. 42 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 42 | Unknown 42 |
| Phase 2 | 4 | Unknown 4 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma Orelabrutinib + R-CHOP, Placebo + R-CHOP - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 3 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 150 | 2022-11-02 | 2024-02-07 |
| ChiCGB vs BEAM in High-risk or R/R Lymphomas Chidamide, Cladribine, Gemcitabine - Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell | Phase 3 | Unknown | Sichuan University | 306 | 2022-07-01 | 2022-07-25 |
| Genotype-guided Treatment in DLBCL Rituximab, Cyclophosphamide, Doxorubicin - Diffuse Large B Cell Lymphoma | Phase 3 | Unknown | Ruijin Hospital | 1100 | 2022-06-01 | 2023-03-24 |
| The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years six courses of zanubrutinib, rituximab and lenalidomide, six courses of rituximab combined with low-dose CHOP - Diffuse Large B-Cell Lymphoma | Phase 3 | Unknown | Ruijin Hospital | 280 | 2022-03-02 | 2023-05-23 |
| Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL Methotrexate - Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma | Phase 3 | Unknown | Peking Union Medical College Hospital | 488 | 2021-10-08 | 2021-09-23 |
| Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-09-14 | 2023-07-25 |
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT PD-1 Inhibitor Tislelizumab maintenance therapy - Lymphoma, Large B-Cell, Diffuse, Transplantation | Phase 3 | Unknown | Ruijin Hospital | 94 | 2021-07-09 | 2021-11-22 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies - High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 3 | Unknown | Shandong Provincial Hospital | 130 | 2021-04-15 | 2021-11-19 |
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT PD-1 Inhibitor Tislelizumab maintenance therapy - Lymphoma, Large B-Cell, Diffuse, Transplantation | Phase 3 | Unknown | Ruijin Hospital | 132 | 2021-04-01 | 2021-03-16 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX - High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 3 | Unknown | Shandong Provincial Hospital | 160 | 2021-03-01 | 2021-12-21 |
| Early Palliative Care for Patients With Haematological Malignancies Early palliative care integration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Unknown | University Hospital, Clermont-Ferrand | 140 | 2019-03-14 | 2021-03-24 |
| Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) TQB2303, Rituximab - Diffuse Large B-cell Lymphoma | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 230 | 2019-01-10 | 2019-05-30 |
| Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines Nebivolol, Placebo - Breast Cancer, Lymphoma, Large B-Cell, Diffuse | Phase 3 | Unknown | Giulio Stefanini | 80 | 2019-01-01 | 2023-02-23 |
| A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients G-CHOP, R-CHOP - Diffuse Large B-Cell Lymphoma, Unspecified Site | Phase 3 | Unknown | Nanjing Yoko Biomedical Co., Ltd. | 360 | 2018-12-28 | 2024-02-20 |
| Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients Thalidomide combined with R-CHOP, R-CHOP - Thalidomide | Phase 3 | Unknown | Fudan University | 162 | 2017-08-22 | 2017-10-24 |
| R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL Rituximab, Etoposide, Doxorubicin - Lymphoma, Large B-Cell, Diffuse | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 402 | 2017-07-27 | 2017-07-28 |
| Thalidomide Maintenance Treatment in DLBCL Thalidomide, Observation - Lymphoma, Large B-Cell, Diffuse | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 226 | 2017-07-26 | 2017-07-28 |
| R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL R-DA-EPOCH, R-CEOP90 - Diffuse Large B-cell Lymphoma | Phase 3 | Unknown | Fujian Medical University | 475 | 2017-07-10 | 2024-03-27 |
| BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2017-07-05 | 2017-10-12 |
| Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma vindesine, cyclophosphamide, Epirubicin - Diffuse, Large B-Cell, Lymphoma | Phase 2 / Phase 3 | Unknown | Xinjiang Medical University | 316 | 2016-09-01 | 2017-07-17 |
Showing 20 of 42. Sign in to see all of them.
Lymphoma, Mantle-Cell (11) · Lymphoma, Follicular (10) · Lymphoma, Non-Hodgkin (10) · Lymphoma (9) · Lymphoma, Large-Cell, Immunoblastic (9) · Burkitt Lymphoma (8) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Lymphoma, B-Cell, Marginal Zone (7) · Hodgkin Disease (4) · Leukemia, Myeloid, Acute (4) · Immunoblastic Lymphadenopathy (3) · Intraocular Lymphoma (3) · Lymphoma, Large-Cell, Anaplastic (3)
Hemic and Lymphatic Diseases (42) · Immune System Diseases (42) · Lymphatic Diseases (42) · Lymphoproliferative Disorders (42) · Neoplasms by Histologic Type (42) · Immunoproliferative Disorders (41) · Neoplasms (41) · Lymphoma, B-Cell (40) · Lymphoma (33) · Lymphoma, Non-Hodgkin (32) · Hematologic Diseases (10) · Leukemia, Lymphoid (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Chronic Disease (8)
Cyclophosphamide (12) · Rituximab (11) · Prednisone (10) · Doxorubicin (9) · Vincristine (9) · Etoposide (6) · Carmustine (4) · Cytarabine (4) · Melphalan (4) · Busulfan (3) · Vindesine (3) · Bleomycin (2) · Gemcitabine (2) · Lenalidomide (2) · Methotrexate (2)
Ruijin Hospital (5) · Nanfang Hospital, Southern Medical University (3) · Gilead Sciences (2) · Shandong Provincial Hospital (2) · Wuhan University (2) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Clatterbridge Centre for Oncology (1) · Commissie Voor Klinisch Toegepast Onderzoek (1) · Czech Lymphoma Study Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · FENG Ji-feng (1) · Fondazione Italiana Linfomi - ETS (1) · Fudan University (1) · Fujian Medical University (1)
China (25) · Italy (5) · United Kingdom (5) · France (3) · United States (3) · Austria (2) · Czechia (2) · Netherlands (2) · Sweden (2) · Switzerland (2) · Belgium (1) · Denmark (1) · Germany (1) · Mexico (1) · Norway (1)
Ru Feng, M.D. (2) · William A. Wegener, MD, PhD (2) · Xin Wang, PhD (2) · Barry J.A. Laird, MD (1) · Bertrand Coiffier, MD (1) · Carmelo Carlo-Stella, MD,Prof (1) · Daobin Zhou, MD. (1) · David C. Linch (1) · Elena N Parovichnikova, MD PhD (1) · Ernest Marshall, MD (1) · Fang-Fang Lv (1) · Gianluigi Condorelli, MD,PhD,Prof (1) · Giulio G Stefanini, MD,PhD,Prof (1) · Heidi Mocikova, M.D., Ph.D. (1) · Jianda Hu, Prof. (1)
PMID 11807147, PMID 12419745, PMID 14998846, PMID 15621843, PMID 15867204, PMID 16754935, PMID 16879771, PMID 17071492, PMID 17400912, PMID 17654614, PMID 17785567, PMID 18005385, PMID 19636553, PMID 20007997, PMID 20548096, PMID 20708263, PMID 21482186, PMID 21707585, PMID 21940215, PMID 24384030, PMID 28668386, PMID 31126528, PMID 31925808, PMID 32817282, PMID 33107145, PMID 37285278, PMID 41123227, PMID 7680764
2015 (1)